Flibanserin (code: BIMT-17), trade name Addyi, was found to be a drug used to treat sexual desire disorder (HSDD) in premenopausal women. Flibanserin was developed by Boehringer Ingelheim, but was negatively evaluated by the US Food and Drug Administration (FDA) in October 2010. Subsequently, the pharmaceutical rights were handed over to the germinated pharmaceutical (en:Sprout Pharmaceuticals) for further research and development, and in August 2015, the US Food and Drug Administration approved. Flibanserin can be increased by 0.5-1 times on a 2-3-time satisfactory sexual behavior in one month compared to placebo. It is the first drug to treat female sexual desire disorders.